Net prices for medicines fell considerably in 2023’s last quarter, mostly thanks to Humira biosimilars; Critics say U.K. decision on ALS drug could have ‘chilling effect’ on access to new genetic medicines

Taking stock of the drug industry, from the lab to the medicine chest

April 1, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Net prices for medicines fell considerably in 2023's last quarter, mostly thanks to Humira biosimilars Net prices for brand-name medicines — after subtracting rebates, discounts, and fees — are expected to continue to decline this year. By Ed Silverman STAT+ | Critics say U.K. decision on ALS drug could have 'chilling effect' on access to new genetic medicines Patient advocates say Biogen officials have indicated to them that the company may not seek regulatory approval for tofersen in the U.K. By Andrew Joseph STAT+ | GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable Analysis by Yale researchers and Doctors Without Borders finds generic insulin and GLP-1 drugs could be much cheaper but still profitable. By Annalisa Merelli Wikimedia Commons STAT+ | Scientists uncover potential path to treating deadly childhood tumor Scientists have long struggled to treat so-called "tumor suppressor" gene cancers. St. Jude researchers may have unlocked a new strategy. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser